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Abstract
To assess the prognostic factors and the outcome in patients with squamous-cell carcinoma of the penis, a retrospective review of
41 consecutive patients with non-metastatic invasive carcinoma of the penis, treated between 1962 and 1994, was performed. The
median age was 59 years (range: 35–76 years). According to the International Union Against Cancer (UICC) 1997 classification,
there were 12 (29%) T1, 24 (59%) T2, 4 (10%) T3 and 1 TX (2%) tumours. The N-classification was distributed as follows: 29
(71%) patients with N0, 8 (20%) with N1, 3 (7%) with N2 and 1 (2%) with N3. Forty-four per cent (n=18) of the patients
underwent surgery: partial penectomy with (n=4) or without (n=12) lymph node dissection, or total penectomy with (n=1) or
without (n=1) lymph node dissection. 23 patients were treated with radiation therapy alone, and all but 4 of the patients who were
operated upon received postoperative radiation therapy (n=14). The median follow-up period was 70 months (range 20–331
months). In a median period of 12 months (range 5–139 months), 63% (n=26) of the patients relapsed (local in 18, locoregional in
2, regional in 3 and distant in 3). Local failure (stump in the operated patients, and the tumour bed in those treated with primary
radiation therapy) was observed in 4 out of 16 (25%) patients treated with partial penectomy postoperative radiotherapy versus
14 out of 23 (61%) treated with primary radiotherapy (P=0.06). 15 (83%) out of 18 local failures were successfully salvaged with
surgery. In all patients, 5- and 10-year survival rates were 57% (95% confidence interval (CI), 41–73%) and 38% (95% CI, 21–
55%), respectively. The 5-year local and locoregional rates were 57% (95% CI, 41–73%) and 48% (95% CI, 32–64%), respectively.
In patients treated with primary radiotherapy, 5- and 10-year probabilities of surviving with penis preservation were 36% (95% CI,
22–50%) and 18% (95% CI, 2–34%), respectively. In multivariate analyses, survival was significantly influenced by the N-classifi-
cation, and surgery was the only independent factor predicting the locoregional control. We conclude that, in patients with squa-
mous-cell carcinoma of the penis, local control is better in patients treated with surgery. However, there seems to be no dierence in
terms of survival between patients treated by surgery and those treated by primary radiotherapy salvage surgery, with 39% having
organ preservation. # 2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Squamous-cell carcinoma of the penis is a rare dis-
ease, and its incidence is estimated at 1/100 000 in the
male population of the North American and European
countries [1]. The mean age at presentation is 60 years.
Many epidemiological studies have suggested that
penile carcinoma is more frequent in uncircumcised
men, poor genital hygiene and human papilloma virus
infection [2–7].
The treatment is traditionally curative surgery [8–12].
However, more conservative modalities, such as exter-
nal radiation and/or interstitial brachytherapy, can also
result in good local control with the advantage of pre-
serving a functional organ in early-stage penile cancers
[13–20]. If this latter option is chosen, surgery can be
reserved for salvage. To our knowledge, there are no
randomised studies comparing dierent treatment
options. Thus, we wanted to assess the prognostic fac-
tors and the outcome in patients with squamous-cell
carcinoma of the penis treated in our department.
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2. Patients and methods
A retrospective study of 41 consecutive patients with
non-metastatic invasive squamous-cell carcinoma of the
penis, treated between 1962 and 1994, was performed.
The median age was 59 years (range: 35–76 years). 8
(20%) patients were circumcised, and only 2 (5%) had a
history of venereal disease. Existence of a penile mass
was the first symptom in 32 (78%) patients. The anato-
mical site was distributed as follows: glans in 17 (41%),
prepuce in 9 (22%), shaft in 8 (20%), coronary locali-
sation in 4 (10%), prepuce and glans in 2 (5%) and
shaft and prepuce in 1 (2%). All of the patients were
classified according to the International Union Against
Cancer (UICC) 1997 classification. Operated patients
were staged pathologically, and those treated with
radiation therapy alone were staged clinically. There
were 12 (29%) T1, 24 (59%) T2, 4 (10%) T3 and 1 TX
(2%) tumours [21]. The N-classification was distributed
as follows: 29 (71%) patients with N0, 8 (20%) with N1,
3 (7%) with N2 and 1 (2%) with N3. 13 (32%) patients
had grade 1, 7 (17%) grade 2 and 9 (22%) grade 3
tumours (grade was not determined in 12 (29%)).
Forty-four per cent (n=18) of the patients underwent
surgery: partial penectomy with (n=4) or without
(n=12) lymph node dissection, or total penectomy with
(n=1) or without (n=1) lymph node dissection. All but
4 of the patients who underwent surgery had primary
(n=23) or postoperative (n=14) radiotherapy (RT) to
the penis and inguinal lymph nodes (n=20), penis alone
(n=9), or inguinal lymph nodes alone (n=8). The
details of the dierent treatment modalities are given in
Table 1. Indications for postoperative radiotherapy
were positive surgical margins and/or lymph node
involvement.
In patients receiving primary RT (n=23), the treat-
ment volume included the penis in all patients (22
external RT including a brachytherapy boost in 4
patients, and 1 patient treated with brachytherapy
alone) and locoregional nodes in 22 patients. The dose
to the penis ranged from 45–74 Gy given in 1.8–2 gray
(Gy)/fractions. The most commonly used radiation dose
was 60 Gy in 30 fractions over 6 weeks. The only patient
treated with low dose rate brachytherapy alone (50–100
cGy/h; Paris system) received 65 Gy using Ir192 wires
guided with Plexiglass templates to maintain the geo-
metry of the implant. 4 patients boosted by low dose
rate interstitial implants (50–100 cGy/h; Paris system),
received a dose ranging from 15–25 Gy. The dose to the
nodal areas ranged from 36 to 66 Gy given in 1.8–2 Gy/
fractions.
Parallel opposed lateral (Co60 or 6 MV photons)
fields were used to encompass the entire length of the
penis. The physical set-up consisted of a rectangular
wax block placed around the shaft of the penis to
achieve a uniform dose distribution according to the
Toronto technique [20].
Locoregional lymph nodes were treated using parallel
opposed anterior posterior/posterior anterior (AP/PA)
fields or the ‘box’ technique using high energy photons
(18 MV). Booster doses to the positive nodes were
delivered using suitable energy electrons.
The median and mean follow-up period was 70 and 96
months, respectively (range: 20–331 months).
Means were compared by Student’s t-test. Propor-
tions were compared using the Chi-square test for
values greater than 5, and Fisher’s exact test for those
less than or equal to 5. Kaplan–Meier product-limit
estimates were used to evaluate the survival, local con-
trol and locoregional control [22]. Time to any event
was measured from the date of pathological diagnosis.
The events were death (all causes of death included) for
overall survival, and local or locoregional relapse for
local and locoregional control (patients who died with-
out local or locoregional relapse were censored at time
of death), respectively. Information pertaining to the
cause of death was always obtained from the clinical
records and/or death certificates. No autopsies were
carried out. 95% Confidence intervals (CI) were calcu-
lated from standard errors. Dierences between groups
were assessed using the logrank test [23]. The Bonfer-
roni method was used to adjust the individual P-values
in order to obtain overall significance levels depending
on the number of parameters tested (P-adjusted equals
individual P-value times the number of parameters tes-
ted) [24]. Multivariate analyses were carried out using
the Cox stepwise regression analysis to determine the
independent contribution of each prognostic factor [25].
3. Results
In a median period of 12 months (range: 5–139
months), 63% (n=26) of the patients relapsed (local in
18, locoregional in 2, regional in 3 and distant in 3).
Local failure was observed in 4 out of 16 (25%) patients
treated with partial penectomy postoperative radio-
therapy compared with 14 out of 23 (61%) treated with
Table 1




Total penectomy and lymph node dissection 1 2
Total penectomy 1 2
Partial penectomy and lymph node dissection 4 10
Partial penectomy 12 29
Radiotherapy
Primary radiotherapy 23 56
Postoperative radiotherapy 14 34
No postoperative radiotherapy 4 10
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primary radiotherapy (P=0.06). Among the 12 patients
with clinically positive lymph nodes, 5 underwent ingu-
inal lymphadenectomy and postoperative radiotherapy
and 7 radiotherapy alone. We observed 3 regional
failures: 2 in the surgery and 1 in the radiotherapy
group. The details are given in Table 2. 15 (83%) out of
18 local failures were successfully salvaged with surgery.
At the time of analysis, among the 23 patients treated
with primary radiotherapy, local control was obtained
with organ preservation in 9 (39%) patients, and with-
out organ preservation in 13 (57%) patients. One
patient (4%) could not be salvaged.
In all patients, 5- and 10-year survival (Kaplan–Meier
product-limit estimates) rates were 57% (95% CI, 41–
73%) and 38% (95% CI, 21–55%), respectively. The 5-
and 10-year local and locoregional control rates were
57% (95% CI, 41–73%) and 39% (95% CI, 21–59%)
and 48% (95% CI, 32–64%) and 33% (95% CI, 16–
40%), respectively.
Table 2
Distribution of the relapses according to dierent treatment modalities





4 (out of 16) 0.06




*Fisher’s exact test (two-sided).
a Relapse on the surgical stump.
b Relapse on the tumour bed.
c Local and inguinal relapse.
d Inguinal relapse alone.
Fig. 1. Overall survival at 10 years according to the primary treatment modality.
Table 3








All patients 41 57 41–73
Clinical T-classification
T1 12 81 58–100 0.33 NS
T2 24 48 28–68
T3 4 0 –
TX 1 – –
Clinical N-classification
N0 29 68 50–86 0.0002 0.001
N1 8 43 6–80
N2 3 25 0–66
N3 1 – –
Histological grade
1 13 54 25–83 0.19 NS
2 7 33 0–70
3 9 39 6–72
? 12 83 62–100
Circumcision
No 33 55 38–72 0.61 NS
Yes 8 69 32–100
Type of treatment
Primary RT 23 62 41–83 0.82 NS
Surgery RT 18 55 30–80
*Bonferroni correction.
NS, non significant; RT, radiotherapy; 95% CI, 95% confidence
interval.
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In univariate analyses, among the various factors
studied (clinical T- and N-classification, histological
grade and the existence of a circumcision), only the
clinical N-classification was a statistically significant
prognostic factor for survival (Table 3). Local and
locoregional control were significantly influenced only
by the type of primary treatment (surgery radio-
therapy versus primary radiotherapy; 81% (95% CI,
44–100%) versus 41% (95% CI, 25–57%) for local
control, P=0.009; 75% (95% CI, 54–96%) versus 31%
(95% CI, 11–51%) for locoregional control, P=0.008).
The type of primary treatment did not influence survival
(Fig. 1). In patients treated with primary radiotherapy,
the 5- and 10-year probabilities of surviving with penis
preservation was 36% (95% CI, 22–50%) and 18%
(95% CI, 2–34%), respectively (Fig. 2). Salvage treat-
ment consisted of excision alone (n=1), partial (n=6)
or total penectomy (n=7) in the 14 local failures in the
primary radiotherapy group (n=23). 4 patients relapsing
in the surgery group (n=18) were salvaged with a total
penectomy.
In multivariate analyses (Cox model), statistically
significant factors influencing the local and locoregional
control were the type of primary treatment (surgery
radiotherapy versus primary radiotherapy; P=0.02
and 0.01, respectively) (Table 4). In contrast, survival
was influenced only by the clinical N-stage (N0, 1 versus
N2, 3; P=0.03).
2 patients (9%) out of 23 patients treated with pri-
mary radiation therapy developed urethral stenosis fol-
lowing treatment, which were reversible after successful
dilatation.
4. Discussion
Penile carcinoma is an uncommon disease in devel-
oped countries while its incidence is higher in the devel-
oping ones. Several risk factors have been reported in
the literature, such as poor genital hygiene, phimosis,
venereal disease, smoking and association with human
papilloma virus infection [2–7]. An important factor
playing a protective role in the genesis of penis carci-
noma is neonatal circumcision as encountered in Mos-
lems and Jews [6,7]. Some authors do not agree with
Fig. 2. Estimated survival with penis preservation at 10 years in 23 patients treated with primary radiotherapy  salvage surgery.
Table 4





Treatment (surgery RTc versus primary RT) 6.25* 0.02
Locoregional controla
Treatment (surgery RTc versus primary RT) 5.65* 0.01
Survivalb
Clinical N-classification (N0, N1c versus N2, N3) 6.05** 0.03
*Surgery RT better than primary RT; **N0, N1 better than N2,
N3. RT, radiotherapy; NS, statistically not significant.
a Analysis also includes clinical N-classification (N0, N1 versus N2,
N3; NS), clinical T-classification (TX, T1, T2 versus T3; NS), histolo-
gical grade (G?, G1 versus G2, G3; NS), tumour fixation (yes versus
no; NS), and elective lymph node irradiation (yes versus no; NS).
b Analysis also includes clinical T-classification (TX, T1, T2 versus
T3; NS), and histological grade (G?, G1 versus G2, G3; NS).
c Reference group.
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that [26]. In our study, the majority of patients (33/41;
80%) were not circumcised.
Narayana and colleagues [9] reported a retrospective
study of 107 patients with penile mass, while a study of
24 patients were also reported in Sweden by Modig and
colleagues [27] and 43 patients by Sarin and colleagues
[28]. In our series, the first symptom was penile mass in
32 patients (78%), and glans and prepuce were the pre-
dominant sites in 28 patients (68%). Rozan and collea-
gues [13] reported in their large survey of 259 patients
with penile carcinoma, 130 with tumour involving the
glans, 44 the prepuce, 83 in both sites and 2 patients
with shaft infiltration alone.
Radical or partial penectomy is traditionally the
standard management of invasive squamous-cell carci-
noma of the penis [8–11,29,30]. It is obvious that local
failure is very low after total penectomy or partial
penectomy (2–6%), however, psychosexual morbidity is
important, and rarely reported in surgical series [31].
Non-mutilating conservative therapies, such as laser
resection, brachytherapy and/or external radiation
therapy are alternative modalities oering good local
control with functional organ preservation [13–20,32,33]
(Table 5). In our series, local failure in patients under-
going partial penectomy postoperative radiotherapy
was 4 out of 16 (25%). There were no relapses either in
the 2 patients who underwent total penectomy or in the
2 patients with positive surgical margins and who
underwent partial penectomy and postoperative radio-
therapy. In our group of 23 patients treated with radio-
therapy as a first curative intent, we observed 14 local
relapses (61%), which is much higher than has been
reported in other conservative treatment series (Table 5).
Among the 14 local failures, only 5 patients received a
total dose 564 Gy, whereas 9 had lower doses.
The management of regional nodes in penile cancer is
controversial. Approximately 20% of the patients with
clinical negative nodes have occult metastases. Inguinal
lymphadenectomy remains questionable for clinically
negative lymph nodes because 80% of the patients with
pathologically uninvolved nodes would receive no ben-
efit from surgery and yet be exposed to significant mor-
bidity [12,34]. It has been suggested that patients with
T2 grade 3, T3, and operable T4 tumours are suitable
candidates for prophylactic inguinal lymphadenectomy
[35]. In our series, we had only 1 clinically node-negative
patient who became pN2 following surgery.
We conclude that, in patients with squamous-cell
carcinoma of the penis, the local relapse rate is lower in
patients treated with surgery. However, there seems to
be no dierence in terms of survival between patients
treated by surgery and those treated by primary radio-
therapy salvage surgery, with 39% having organ pre-
servation. For small tumours, primary radiotherapy
seems to be a reasonable treatment option if close fol-
low-up is implemented, so that an important proportion
of patients can have organ preservation. Nevertheless,
with the introduction of better conformal techniques
and/or the introduction of concomitant chemotherapy
in future collaborative multicentric studies, better organ
preservation can be obtained with less morbidity in this
relatively rare malignancy.
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